News and Updates

iVeena appoints Jerry Simmons as CEO and Director

16 February 2015

Mr. Simmons brings more than 30 years of large pharmaceutical and early stage drug development company experience. This experience includes several corporate licensing transactions, participation in several company financings and two successful Initial public Offerings. Most recently, Mr. Simmons held the position of corporate business development officer at Lipocine Inc. from 2003 to 2014. Mr. Simmons has held corporate business positions at Pharmacraft (now Ciba-Geigy) and served in various senior marketing positions at Schering Plough Corp. (now Merck & Co) from 1997 to 1984. He served as the chief executive officer of Cellegy Pharmaceuticals, a drug delivery company from 1991 to 1996. From 1996 to 2001, he served as the chief executive officer of MantiCore Pharmaceuticals, an oncology company and Fountain Pharmaceuticals, a drug delivery company. He served as Managing Partner of The Planning Board, a technology consulting company from 2001 to 2003. Mr. Simmons received a B.A. from Canisius College and a M.B.A. from the University of Buffalo.

iVeena promotes Michael Burr Vice President, Product development

10 February 2015

Mr. Burr has over 7 years of experience in ocular drug delivery and device development. From 2008 to 2009, Mr. Burr was a fellow at the Lassonde Entrepreneur Institute. Beginning in June 2009, Mr. Burr was hired as a Drug Delivery Scientist at iVeena where he oversaw drug delivery research & development in neovascular age-related macular degeneration and glaucoma. Upon promotion to Vice President of Product Development in 2015, Mr. Burr now oversees the commercial development of iVeena’s pipeline. Mr. Burr holds Bachelor’s and Master’s degrees in biomedical engineering from the University of Utah and also holds an M.B.A. from the David Eccles School of Business at the University of Utah.

iVeena publishes Proof of Concept studies for Post Surgery Cataract Inflammation products

20 November 2013

iVeena has demonstrated safety and efficacy in 42 rabbit eyes in treating post-surgical inflammation and retinal thickening (as measured by optical coherence tomography). iVeena has also demonstrated appropriate and desired first-order release kinetics of dexamethasone. iVeena has been able to reproducibly manufacture implants using a method of hot-melt extrusion that is scalable, operable with our equipment, in a clean-room GMP environment, and sterilizable with e-beam radiation and package-able with a vacuum sealed pouch.